Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III.

Molecular brain - 10 Dec 2015

Jun Mi-Hee, Han Jeong-Ho, Lee Yu-Kyung, Jang Deok-Jin, Kaang Bong-Kiun, Lee Jin-A

Abstract excerpt

BACKGROUND: Transmembrane protein 106B (TMEM106B) has been identified as a risk factor for frontotemporal lobar degeneration, which is the second most common form of progressive dementia in people under 65 years of age. Mutations in charged multivesicular body protein 2B (CHMP2B), which is involved in endosomal protein trafficking, have been found in chromosome 3-linked frontotemporal dementia. Despite the number...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endosomal Sorting Complexes Required for Transport
Share to Endosomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Frontotemporal Dementia

Share to Nerve Degeneration

Share to Protein Interaction Maps

Share to rab GTP-Binding Proteins

Share to rab5 GTP-Binding Proteins

Share to rab7 GTP-Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26651479
DOI: 10.1186/s13041-015-0177-z
PMCID: PMC4676093

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III.PMID 26651479Read ↗

Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes.Semantic proximity Read ↗

The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and functionSemantic proximity Read ↗

What we know about TMEM106B in neurodegeneration.Semantic proximity Read ↗

TMEM106B aggregation in neurodegenerative diseases: linking genetics to function.Semantic proximity Read ↗

Physiological and pathological functions of TMEM106B in neurodegenerative diseases.Semantic proximity Read ↗

Granulin loss and TMEM106B risk converge on lysosomal C-terminal fragment pathology in frontotemporal dementiaSemantic proximity Read ↗

TMEM106B expression is reduced in Alzheimer’s disease brainsSemantic proximity Read ↗

Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration.Semantic proximity Read ↗

Divergent and Convergent TMEM106B Pathology in Murine Models of Neurodegeneration and Human DiseaseSemantic proximity Read ↗

Loss of TMEM106B exacerbates Tau pathology and neurodegeneration in PS19 miceSemantic proximity Read ↗

Loss of TMEM106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in miceSemantic proximity Read ↗

TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.